A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.

Date publication

novembre 2017

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LADOIRE Sylvain , Dr THIERY-VUILLEMIN Antoine

Tous les auteurs :
Fizazi K, Ulys A, Sengeløv L, Moe M, Ladoire S, Thiery-Vuillemin A, Flechon A, Guida A, Bellmunt J, Climent MA, Chowdhury S, Dumez H, Matouskova M, Penel N, Liutkauskiene S, Stachurski L, Sternberg CN, Baton F, Germann N, Daugaard G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29059273

Résumé

This phase II study was conducted to assess clinical efficacy of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer not progressing during first-line docetaxel-based therapy.

Mots clés

Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Disease Management, Double-Blind Method, Follow-Up Studies, Humans, International Agencies, Male, Middle Aged, Prognosis, Prostatic Neoplasms, Castration-Resistant, drug therapy, Quality of Life, Quinolones, administration & dosage, Survival Rate, Taxoids, administration & dosage, Treatment Outcome

Référence

Ann. Oncol.. 2017 Nov 1;28(11):2741-2746